Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial - Nishio, M; Yoshida, T; Kumagai, T (J Thorac Oncol, 2021)
et al.